Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia

References

• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-35
   PubMed Web of Science ®Google Scholar
• Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):601-16
   PubMed Web of Science ®Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006(2):CD000543
   Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006(2):CD000544
   PubMed Web of Science ®Google Scholar
• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):617-29
   PubMed Web of Science ®Google Scholar
• Tang J, Sharif O, Pai C, Silverman AL. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010;55(6):1696-703
   PubMed Web of Science ®Google Scholar
• Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8(12):1179-83
   PubMed Web of Science ®Google Scholar
• Hanauer S, Present DH, Jones WK. The state of the art in the management of inflammatory bowel disease: update and recent advances in colorectal cancer prevention. Clin Courier 2004;22:1-8
   Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100(6):1345-53
   PubMed Web of Science ®Google Scholar
• Lopez A, Peyrin-Biroulet L. 5-Aminosalicylic acid and chemoprevention: does it work? Dig Dis 2013;31(2):248-53
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4(1):28-62
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6(10):991-1030
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: australia-wide experience, 2004-2006. Med J Aust 2008;188(4):224-7
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy – experience in Australia 2006-2010. Aust Fam Physician 2011;40(5):319-22
   PubMedGoogle Scholar
• Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med J Aust 2011;195(3):134-7
   PubMed Web of Science ®Google Scholar
• Australian Government. Available from: www.medicareaustralia.gov.au [Last accessed 7 January 2014]
   Google Scholar
• Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114(1):39-43
   PubMed Web of Science ®Google Scholar
• Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53(4):1020-4
   PubMed Web of Science ®Google Scholar
• Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther 2013;38(5):531-8
   PubMed Web of Science ®Google Scholar
• Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol 2013;13:23
   PubMed Web of Science ®Google Scholar
• Selinger CP, Andrews J, Dent OF, et al. Cause-specific mortality and 30-year relative survival of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2013;19(9):1880-8
   PubMed Web of Science ®Google Scholar
• Selinger CP, Andrews JM, Titman A, et al. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24(2):157-65
   PubMed Web of Science ®Google Scholar
• Selinger C, Eaden J, Jones B, et al. Modifiable factors associated with nonadherence to maintenancemedication for inflammatory bowel disease. Inflamm Bowel Dis 2013;19(10):2199-206
   PubMed Web of Science ®Google Scholar
• Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf 2011;10(6):863-70
   PubMed Web of Science ®Google Scholar